ポンペ病治療薬の世界市場2015-2019

◆英語タイトル:Global Pompe Disease Market 2015-2019
◆商品コード:IRTNTR5625
◆発行会社(調査会社):Technavio
◆発行日:2015年4月8日
◆ページ数:71
◆レポート言語:英語
◆レポート形式:pdf
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥257,500見積依頼/購入/質問フォーム
Five UserUSD3,000 ⇒換算¥309,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥412,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。



当調査レポートでは、ポンペ病治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、ポンペ病治療薬の世界市場規模及び予測、市場シェア、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。
【レポートの概要】

About Pompe Disease
Pompe disease is a type of LSD. LSD refers to a group of diseases arising from the accumulation of specific substrates. LSDs are progressive and have variable age of onset and clinical symptoms. LSDs are inherited autosomal recessive disorders. Pompe disease has two broad sub-types: infantile-onset Pompe disease and adult-onset Pompe disease. Pompe disease occurs as a result of mutations in the GAA gene. These mutations are responsible for the preventing the action of the enzyme acid alpha-glucosidase, which is responsible for catabolizing glycogen, thereby allowing sugar to accumulate and reach toxic levels in the lysosomes of cells. The buildup of glycogen in certain organs and tissues, mostly in the muscles, hinders the normal functions of organs. Pompe disease is an autosomal recessive disease. This implies that both the parents pass on one abnormally mutated copy of the gene to their child. A parent carrying an abnormal copy of the gene is known as a carrier. Pompe disease affects both men and women, irrespective of the gender. Pompe disease affects people across all ethnicities and races. Individuals affected with Pompe disease acquire the disease at birth, however, the onset of symptoms varies extensively. More than 300 genetic mutations that can cause Pompe disease have been identified by the researchers till date. Though there is no cure for Pompe disease, diet therapy and enzyme replacement therapy are effective in reducing the clinical manifestations of the disease.

TechNavio’s analysts forecast the Global Pompe Disease market to grow at a CAGR of 11.79 percent over the period 2014-2019.

[Covered in this Report]
This report covers the present scenario and the growth prospects of the Global Pompe Disease market for the period 2015-2019. To calculate the market size, the report considers revenue from the sales of drugs available in the market for the management of Pompe disease.

The report also presents the vendor landscape and a corresponding detailed analysis of the major vendors in the Global Pompe Disease market. The report also considers the revenue that is likely to be generated from the drug candidates that are under various phases of development. In addition, it discusses the major drivers that influence the growth of the market, the challenges faced by the vendors and the market at large, as well as the key trends that contribute to the growth the market.

TechNavio’s report, Global Pompe Disease Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Pompe Disease market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key Regions]
• Americas
• APAC
• EMEA

[Key Vendors]
• Amicus Therapeutics
• BioMarin Pharmaceutical
• Genzyme

[Other Prominent Vendors]
• Audentes Therapeutics
• EpiVax
• Oxyrane
• Sangamo BioSciences
• Valerion Therapeutics

[Market Driver]
• Special Provisions for Orphan Drugs
• For a full, detailed list, view our report

[Market Challenge]
• Limited Patient Population
• For a full, detailed list, view our report

[Market Trend]
• Regulatory Assistance in Emerging Nations
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【レポートの目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology

05.Introduction

06.Disease Overview
06.1 Understanding the Disease
06.1.1 Types of Pompe Disease
06.1.2 Symptoms
06.1.3 Diagnosis
06.2 Etiology and Pathogenesis
06.2.1 Biochemical Pathway
06.3 Epidemiology
06.4 Management
06.5 Economic Burden

07.Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis

08.Pipeline Analysis
08.1 Key Information on Pipeline Candidates
08.1.1 rAAV1-CMV-GAA
08.1.2 OXY-2810
08.1.3 Tregitopes for Pompe Disease
08.1.4 AT-002
08.1.5 ZFP Transcription Factors for LSDs
08.1.6 VAL-1221

09.Geographical Segmentation

10.Buying Criteria

11.Market Growth Drivers

12.Drivers and their Impact

13.Market Challenges

14.Impact of Drivers and Challenges

15.Market Trends

16.Trends and their Impact

17.Vendor Landscape
17.1 Competitive Scenario
17.1.1 Key News
17.1.2 Mergers and Acquisitions
17.2 Market Share Analysis 2014
17.2.1 Genzyme
17.2.2 BioMarin Pharmaceutical
17.2.3 Amicus Therapeutics
17.3 Other and Future Prominent Vendors

18.Key Vendor Analysis
18.1 Amicus Therapeutics
18.1.1 Key Facts
18.1.2 Business Overview
18.1.3 Business Strategy
18.1.4 Key Developments
18.1.5 SWOT Analysis
18.2 BioMarin Pharmaceutical
18.2.1 Key Facts
18.2.2 Business Overview
18.2.3 Segmentation by Revenue 2014
18.2.4 Segmentation by Revenue 2013 and 2014
18.2.5 Geographical Segmentation by Revenue 2014
18.2.6 Business Strategy
18.2.7 Recent Developments
18.2.8 SWOT Analysis
18.3 Genzyme
18.3.1 Key Facts
18.3.2 Business Overview
18.3.3 Product Segmentation by Revenue 2013
18.3.4 Product Segmentation by Revenue 2012 and 2013
18.3.5 Geographical Segmentation
18.3.6 Business Strategy
18.3.7 Recent Developments
18.3.8 SWOT Analysis

19.Other Reports in this Series

[List of Exhibits]

Exhibit 1: Market Research Methodology
Exhibit 2: Snapshot of Pompe Disease
Exhibit 3: Heredogram of Pompe Disease
Exhibit 4: Types of Pompe Disease
Exhibit 5: Signs and Symptoms of Pompe Disease
Exhibit 6: Differential Diagnosis of Pompe Disease in Infants
Exhibit 7: Differential Diagnosis of Pompe Disease in Children and Adults
Exhibit 8: Biochemical Pathway of Pompe Disease
Exhibit 9: Approaches to Treat Pompe Disease
Exhibit 10: Economic Burden of Pompe Disease
Exhibit 11: Snapshot of Global Pompe Disease Market 2014
Exhibit 12: Global Pompe Disease Market 2014-2019 (US$ million)
Exhibit 13: Drivers and Challenges of Global Pompe Disease Market
Exhibit 14: Pipeline Portfolio of Global Pompe Disease Market
Exhibit 15: Segmentation of Global Pompe Disease Market by Geography 2014
Exhibit 16: Genzyme: Product Portfolio
Exhibit 17: BioMarin Pharmaceutical: Segmentation by Revenue 2014
Exhibit 18: BioMarin Pharmaceutical: Segmentation by Revenue 2013 and 2014 (US$ million)
Exhibit 19: BioMarin Pharmaceutical: Geographical Segmentation by Revenue 2014
Exhibit 20: Genzyme: Product Segmentation by Revenue 2013
Exhibit 21: Genzyme: Product Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 22: Genzyme: Geographical Segmentation



【掲載企業】

Amicus Therapeutics, BioMarin Pharmaceutical, Genzyme , Audentes Therapeutics, EpiVax, Oxyrane, Sangamo BioSciences , Valerion Therapeutics

【レポートのキーワード】

ポンペ病、ライソゾーム病、治療薬、医薬品、医療

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[ポンペ病治療薬の世界市場2015-2019]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。H&I文字はH&Iグローバルリサーチ株式会社の商標(登録第5783645号)です。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。
※当サイトでは2016年07月01日現在 193,849 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆